Cancer Res Treat. 2002 Feb;34(1):62-6. doi: 10.4143/crt.2002.34.1.62.
To evaluate the efficacy of sclerotherapy with OK-432 for lymphangiomas.
Retrospective review of twelve patients with lymphangiomas who were treated with OK-432 from 1996 to 2000.
Twelve patients were treated by sclerotherapy with OK-432. Ten patients were received sclerotherapy with OK-432 as primary therapy, and two were treated as secondary therapy after failure of surgery. Six cases were cystic hygroma (macrocystic); all of them, complete shrinkage was obtained. The other six cases were cavernous lymphangioma (microcystic): two of them, therapy were successful, but four were failed to achieve satisfactory shrinkage. So, they underwent surgical excision after failure of sclerotherapy. The results were excellent in cystic hygroma (success rate; 100%), however moderately poor results were obtained in cavernous lymphangioma (success rate 33.3%).
Intralesional injection of OK-432 is effective therapy for cystic hygroma as a primary therapy.
评估 OK-432 硬化疗法治疗淋巴管瘤的疗效。
回顾性分析 1996 年至 2000 年间接受 OK-432 治疗的 12 例淋巴管瘤患者。
12 例患者接受 OK-432 硬化疗法治疗。10 例患者接受 OK-432 硬化疗法作为一线治疗，2 例患者在手术失败后接受二线治疗。6 例为囊状淋巴管瘤（大囊型）；所有患者均获得完全退缩。另外 6 例为海绵状淋巴管瘤（小囊型）：2 例治疗成功，4 例未能获得满意的退缩，因此在硬化治疗失败后行手术切除。囊状淋巴管瘤的治疗效果极佳（成功率 100%），而海绵状淋巴管瘤的治疗效果中等（成功率 33.3%）。
腔内注射 OK-432 是治疗囊状淋巴管瘤的有效方法，可作为一线治疗。
